The Latest Psoriasis Journal Articles
Keep up to date with the latest in psoriasis. Check out the latest psoriasis articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily.
- Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated by numerous cytokines produced by drug specific T-cells that mediate neutrophilic intracorneal, subcorneal, and/or intraepidermal pustule development. Though genetic susceptibility is not fully understood, individuals […]
- Clinical Presentation and Management of Atypical and Recalcitrant Acute Generalized Exanthematous Pustulosis (AGEP).Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction (SCAR) characterized by sterile non-follicular pustules on an erythematous base that form rapidly after drug exposure. AGEP is mediated by numerous cytokines produced by drug specific T-cells that mediate neutrophilic intracorneal, subcorneal, and/or intraepidermal pustule development. Though genetic susceptibility is not fully understood, individuals […]
- Assessing work-related productivity loss and indirect costs of psoriasis across six countries.Psoriasis is a skin disease that can negatively impact on patients’ psychosocial well-being. It affects millions of people worldwide. The overall economic burden (meaning the cost to the economy) of psoriasis is severe; however, no study has fully assessed it due to a lack of comparable data from different countries. This study looked at work […]
- The epidemiology of hidradenitis suppurativa.Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease defined clinically by multiple, painful inflammatory lesions occurring predominantly in flexural sites. Onset is typically soon after puberty; however, it remains unknown whether the menopause induces remission. In North American and European patients with HS the female-to-male ratio is approximately 3 : 1 but the ratio is 1 : 2 […]
- A Head-to-Head Comparison of Ixekizumab Versus Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis: 24-Week Efficacy and Safety Results from a Randomised, Double-Blinded Trial.Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area and Severity Index (PASI 100) at Week 12.To compare skin and nail clearance and patient-reported outcomes for ixekizumab vs. guselkumab, up to Week 24.IXORA-R enrolled […]
- Modifiable Lifestyle and Environmental Factors Associated with Onset of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.Psoriatic arthritis (PsA) is a progressive joint disease associated with psoriasis.To investigate the association of modifiable lifestyle and environmental factors with PsA risk among people with psoriasis.We conducted a systematical search of PubMed, EMBASE and Cochrane Library up to 2 May 2020 for observational studies reporting lifestyle or environmental factors for PsA onset in psoriasis […]
- Comorbidities in patients with palmoplantar plaque psoriasis.Psoriasis has been shown to be associated with several comorbidities. Whether the palmoplantar subtype of plaque psoriasis carries similar risks for comorbidities as generalized plaque psoriasis remains to be defined.To examine the association between palmoplantar plaque psoriasis and comorbidities known to be associated with generalized plaque psoriasis.We retrospectively compared the prevalence of comorbidities previously found to be […]
- Reduced Risk of Mortality Associated With Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A Nested Case-Control Analysis.The effects of systemic therapy on mortality risk among patients with psoriasis are not fully understood.To evaluate the impact of systemic treatment on mortality risk in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).Nested case-control analyses were performed to estimate mortality risk. Cases were defined as patients who died while participating in PSOLAR. […]
- The association of psoriasis and hypertension: focusing on anti-inflammatory therapies and immunological mechanisms.Psoriasis is a chronic skin disease characterized by recurrent inflammation, and is increasingly being recognized as a systemic inflammatory disorder, which is associated with cardiovascular events, metabolic syndrome, diabetes, obesity and hypertension. Recent findings have suggested a greater risk of hypertension, particularly difficult-to-control hypertension, in patients with severe psoriasis. Additionally, abnormal activation of immune cells […]
- A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis.The transcription factor retinoic acid-related orphan receptor 2 (RORC2/RORγT) mediates interleukin (IL)-17A and IL-17F expression. IL-17A plays a central role in the pathogenesis of several inflammatory disorders, including psoriasis. The RORC2 inhibitor PF-06763809 has been hypothesized to inhibit IL-17A production in T-helper 17 (Th17) cells, thereby reducing psoriasis symptoms.To assess the safety, tolerability, and effect […]
- Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership.Psoriasis impacts the health and psychosocial functioning of patients, conferring a significant economic burden on healthcare systems. There remain unmet needs in psoriasis care, which if addressed by research, could improve clinical outcomes.Between July 2017 and November 2018 we conducted a Priority Setting Partnership for psoriasis (PsPSP). We invited those with lived-experience of psoriasis and […]
- Axial psoriatic arthritis: An update for dermatologists.Psoriasis is a chronic, immune-mediated, systemic, inflammatory disorder characterized by skin plaques and, often, nail disease and arthritis that contribute to reduced quality of life. Psoriatic arthritis-a heterogeneous, inflammatory, musculoskeletal disease that can cause permanent damage to both peripheral and axial joints-is the most common comorbidity of psoriasis. Axial disease occurs in 25% to 70% […]
- fJoint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine (AM) will be reviewed, emphasizing treatment recommendations […]
- Management of nail psoriasis.Nail involvement is estimated to affect 80-90% of patients with psoriasis at some point in their lives and is often associated with severe disease. Patients with nail involvement experience pain, functional impairment and social stigma, with significant restriction of daily activities and quality of life. Nail psoriasis is also considered a risk factor for the […]
- Shades of grey: what is paediatric psoriasiform dermatitis and what does it have in common with childhood psoriasis?While the majority of children with a chronic itchy rash suffer from atopic dermatitis (AD) and other forms of dermatitis, psoriasis is in the differential diagnosis. Certain patterns such as guttate and napkin psoriasis are accepted as classic paediatric psoriasis (PP), however there are many patients who do not fit these classic forms of OO […]
- Efficacy of a second IL-17 inhibitor in patients with psoriasis: a systematic review and meta-analysis.Multiple biologics for psoriasis exist and interleukin (IL)-17 inhibitors are among those with best efficacy. However, switching treatment is often required at some point and intraclass switch of IL-17 inhibitors is not well investigated.To determine the efficacy of a second IL-17 inhibitor in patients with psoriasis.Two independent authors searched the databases PubMed and EMBASE for […]
- Trial of Roflumilast Cream for Chronic Plaque Psoriasis.Systemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis.In this phase 2b, double-blind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream, […]
- Long-Term Efficacy of Certolizumab Pegol for the Treatment of Plaque Psoriasis: Three-Year Results from Two Randomised Phase 3 Trials (CIMPASI-1 and CIMPASI-2).Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.Report three-year efficacy, pooled from CIMPASI-1 (NCT02326298) and CIMPASI-2 (NCT02326272) CZP in plaque psoriasis (PSO) phase 3 trials.Adults with moderate to severe PSO for ≥6 months were randomised 2:2:1 to CZP 200 mg, CZP 400 mg, placebo, every two weeks (Q2W) for up to 48 […]
- Secukinumab two weekly versus four weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study.Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A and shows long lasting efficacy and safety in plaque psoriasis. More evidence is required to optimize secukinumab dosing according to clinical response.GAIN compared the efficacy and safety of secukinumab 300 mg every two weeks (q2w) with 300mg every 4 weeks (q4w) in patients achieving […]
- Role of regulatory T cells in psoriasis pathogenesis and treatment.Psoriasis is a chronic inflammatory disease with a strong genetic component that can be triggered by environmental factors. Disease pathogenesis is mainly driven by type 1 and type 17 cytokine-producing cells which, in healthy individuals, are modulated by regulatory T cells (Tregs). Tregs play a fundamental role in immune homeostasis and contribute to the prevention of autoimmune disease […]
- Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial.Patients with plaque psoriasis treated with biologic therapies need more efficacious, safe, and convenient treatments to improve quality of life. Risankizumab and secukinumab inhibit interleukin (IL)-23 and IL-17A, respectively, and are effective in adult patients with moderate-to-severe plaque psoriasis but have different dosing regimens.Directly compare efficacy and safety of risankizumab vs. secukinumab over 52 weeks.IMMerge […]
- Pilot study: immunohistochemistry expressions of vitamin D receptor associated with severity of disease in psoriasis patients.Psoriasis is a chronic inflammatory skin disorder characterized by keratinocyte hyperproliferation, differentiation abnormalities, and resistance to apoptosis. There are several factors that can affect psoriasis and vitamin D is one of the recently arisen. The role of vitamin D is mediated by vitamin D receptors (VDR) in target cells. VDR is a nuclear hormone that […]
- Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-α inhibitor-induced psoriasis: A case-control study.Tumor necrosis factor-α inhibitor-induced psoriasis (TNFI-psoriasis) is a paradoxical reaction characterized by development of a psoriasiform rash that mimics psoriasis vulgaris. Temporal onset variability and low incidence rates suggest underlying risk factors and/or outside triggers may play a role in TNFI-psoriasis initiation.We aimed to identify underlying risk factors/outside triggers associated with TNFI-psoriasis onset.This case-control study […]
- Research Letter Measuring quality in psoriasis: early experiences with the MIPS 410 quality measure-cross sectional study.Click here to read the full article @ Journal of the American Academy of Dermatology
- Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study.Click here to read the full article @ Journal of the American Academy of Dermatology
- Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis.The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to better inform treatment decisions and specifically, to inform guideline development.We searched MEDLINE, PubMed, EMBASE and Cochrane databases for randomized controlled trials (RCTs),published up to 7th September 2018, of 11 licensed, NICE-approved biologics targeting TNF(adalimumab, etanercept, […]
- Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic.Click here to read the full article @ The British journal of dermatology
- Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomised, Placebo-Controlled Studies.Certolizumab pegol (CZP) is an Fc-free, PEGylated anti-tumour necrosis factor biologic.Report three-year safety from three phase 3 trials of CZP in adults with plaque psoriasis (PSO).Data were pooled from CIMPASI-1 (NCT02326298), CIMPASI-2 (NCT02326272), CIMPACT (NCT02346240). Included patients: had moderate to severe PSO ≥6 months; were randomised to CZP 200 mg every two weeks (Q2W) (400 […]
- Psoriasis: Knowledge, Attitudes and Perceptions among Primary Care Providers.Click here to read the full article @ Journal of the American Academy of Dermatology
- What are the barriers to physical activity in patients with chronic plaque psoriasis?Click here to read the full article @ The British journal of dermatology
- Biologics for psoriasis: what does drug survival tell us?Click here to read the full article @ The British journal of dermatology
- No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.Click here to read the full article @ Journal of the American Academy of Dermatology
- Treatment persistence in paediatric and adolescent psoriasis patients followed into young adulthood: from topical to systemic treatment – a prospective, longitudinal, observational cohort study of 448 patients.Although solely topical treatment often suffices, psoriasis patients may require more intensive treatment (phototherapy and/or systemic treatments) to control their disease. However, in paediatric, adolescent and young adult patients, little is known about persistence of topical treatment and time until switch to systemic treatment.To determine median time from psoriasis onset until i) solely topical discontinuation […]
- Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis.Psoriasis is a T-helper cell mediated chronic immune mediated inflammatory disease affecting mainly the skin, although systemic pathological effects are also observed. Cytokine-mediated interaction between T lymphocytes and keratinocytes lead to excessive proliferation of keratinocytes, which in turn leads to formation of a pro-inflammatory milieu and finally to psoriatic plaque formation. This study was designed […]
- Efficacy and Patient-Reported Outcomes from a Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Adolescents and Adults with Atopic Dermatitis.Tapinarof is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for atopic dermatitis (AD) and psoriasis treatment.Phase IIb, double-blind, vehicle-controlled study randomized adolescents and adults with AD to receive tapinarof cream 0.5%, 1%, or vehicle, once (QD) or twice daily (BID) for 12 weeks with 4-week follow-up. Outcomes included Investigator Global Assessment […]
- Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.Secukinumab, a fully human monoclonal antibody that selectively neutralises interleukin-17A, a cornerstone cytokine in psoriasis, has shown long-lasting efficacy and safety in the complete spectrum of psoriasis manifestations.To report the long-term (2.5-year) efficacy and safety of secukinumab in nail psoriasis.TRANSFIGURE, a double-blind, randomised, placebo-controlled, parallel-group, multicentre Phase 3b study in 198 patients, investigated secukinumab 150 […]
- Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.Dual neutralization of both interleukin-17A and interleukin-17F with the monoclonal antibody bimekizumab may have greater efficacy in psoriasis than neutralization of interleukin-17A alone.To provide longer-term efficacy and safety data for bimekizumab from a phase 2b extension study in patients with moderate-to-severe psoriasis (BE ABLE 2, NCT03010527).After the 12-week initial study (BE ABLE 1), patients who […]
- Association between psoriasis and risk of dementia: a systematic review and meta-analysis.Click here to read the full article @ Journal of the American Academy of Dermatology
- Improvement of 11 patients with nail psoriasis with apremilast: results of an investigator-initiated open-label study.Click here to read the full article @ Journal of the American Academy of Dermatology
- A Phase IIb, Randomized Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis: Secondary Efficacy and Patient-Reported Outcomes.Tapinarof cream is a topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) under investigation for treatment of psoriasis and atopic dermatitis.In a phase IIb, double-blind, vehicle-controlled study, adults with plaque psoriasis were randomized to tapinarof cream 0.5% or 1% once (QD) or twice daily (BID) or vehicle QD or BID for 12 weeks with 4-week […]
- Meta-analysis results do not reflect the real safety of biologics in psoriasis.In systematic reviews (SR) and meta-analyses (MA) of randomized controlled trials (RCTs) assessing treatments of psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo. Including cases of psoriasis worsening as SAEs may explain the lack of difference. This SR and MA aimed to explore this possibility.Among the 140 RCTs […]
- PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis.The product of the Physician Global Assessment and body surface area (PGA×BSA) is simpler to use than the Psoriasis Area and Severity Index (PASI), which lacks sensitivity in patients with mild psoriasis.To compare the PGA×BSA versus the modified PASI (mPASI) for assessing disease severity and therapeutic response to calcipotriol/betamethasone dipropionate (Cal/BD) foam.This post hoc analysis evaluated […]
- Dimethyl fumarate modulates the Treg:Th17 cell axis in psoriasis patients.Dimethyl fumarate (DMF) is the active ingredient of Skilarence™ and Tecfidera™ which are used for the treatment of psoriasis and multiple sclerosis, respectively. Various immunomodulatory mechanisms of action have been identified for DMF; however, it is still unclear what effects DMF exerts in vivo in psoriasis patients.In this study we examined the effects of DMF, […]
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.Approximately 125 million people worldwide have psoriasis. Patients with psoriasis experience substantial morbidity and increased rates of inflammatory arthritis, cardiometabolic diseases, and mental health disorders.Plaque psoriasis is the most common variant of psoriasis. The most rapid advancements addressing plaque psoriasis have been in its pathogenesis, genetics, comorbidities, and biologic treatments. Plaque psoriasis is associated with […]
- Dermoscopy in differential diagnosis of inflammatory dermatoses and mycosis fungoides.The use of dermoscopy for the evaluation of various inflammatory dermatoses has witnessed a gradual increase in recent years. The present study describes and highlights the importance of dermoscopic findings in the differential diagnosis of plaque psoriasis (PP), lichen planus (LP), mycosis fungoides (MF), pityriasis rosea (PR), and nummular dermatitis (ND) that mostly involve the […]
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal.The last two decades have seen a rapid growth of targeted biologic therapies for moderate-to-severe plaque psoriasis. While undoubtedly a boon for patients and their treating clinicians alike, the growing number of highly efficacious drug options can make treatment choice challenging. As such, head-to-head randomized controlled trials (RCTs) are necessary to compare the efficacy and […]
- The landscape of psoriasis provision in the UK.Psoriasis remains one of the commonest conditions seen in dermatological practice, and its treatment is one of the greatest cost burdens for the UK NHS. Treatment of psoriasis is complex with numerous overlapping lines and modalities of therapy employed in combination. This complexity reflects the underlying pathophysiology of the disease as well as the heterogenous […]
- Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review.Mesenchymal stem cells (MSCs) have recently been shown to have not only regenerative capabilities but also immunomodulating properties. For this reason, they are currently under investigation in clinical trials for the treatment of several autoimmune systemic disorders. Psoriasis is a systemic immune-mediated disease for which MSCs could have therapeutic potential. We analysed the existing literature […]
- Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation.Although there is increased understanding of the alopecia areata/AA pathogenesis based on studies in scalp tissues, little is known about its systemic profile.To evaluate the blood proteomic signature of AA and determine biomarkers associated with increased disease severity.In a cross-sectional study, we assessed 350 inflammatory and cardiovascular proteins using OLINK high-throughput proteomics in moderate-to-severe AA […]
- Treatment of nail psoriasis with intramatricial methotrexate: An uncontrolled prospective study of 20 patients.Click here to read the full article @ Journal of the American Academy of Dermatology
- The global, regional, and national burden of psoriasis in 195 countries and territories, 1990-2017: A systematic analysis from the Global Burden of Disease Study 2017.Few existing studies on the global incidence, prevalence, and burden of disease from psoriasis are of high quality, making reliable data and comparisons difficult to find.We analyzed global psoriasis trends from 1990 to 2017 in 195 countries worldwide through the Global Burden of Disease Study (GBD) database, including age-standardized prevalence rates, percent change in age-standardized […]
- Real life efficacy and safety of secukinumab in elderly psoriasis patients over a 2-year period.Psoriasis prevalence is increasing among elderly subjects. Elderly psoriasis patients represent a challenge for dermatologists due to multiple comorbidities, polypharmacy, immune senescence which lead to increased possibility of adverse events, drug interactions and susceptibility to cancers and infections. Therefore, conventional systemic therapies are often contraindicated with biologics appearing as mainstay for moderate-to-severe disease. However, data […]
- A retrospective review of pregnancies on biologics for the treatment of dermatological conditions.Psoriasis often first presents in young adulthood, indeed the average age of diagnosis in women is 28, thus in the prime reproductive years. In addition, approximately 50% of pregnancies worldwide are unplanned. Although biologic therapies have revolutionised the treatment of moderate-to-severe psoriasis, there are no controlled studies of biologics in pregnant women. The increasing use […]
- Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender.There is a lack of any overview of changes over time and variation in the epidemiology of psoriasis with age and between genders.To perform a systematic review of published population-based studies on variations in psoriasis incidence and prevalence with age and between genders, and to explore trends in psoriasis epidemiology over time.Eleven electronic and regional […]
- Malignancy and Infection Risk During Adalimumab Therapy in Hidradenitis Suppurativa.The association of Adalimumab therapy with malignancy and infection is established in other inflammatory diseases, however, rates in HS are based on case reports/ retrospective healthcare data and the effect of Adalimumab therapy on these rates is unknown. Previously reported rates in the PIONEER OLE Phase 3 study only reported on rates in a subpopulation […]
- The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis.As biological agents have been widely used for the treatment of psoriasis, increasing numbers of interstitial lung disease (ILD) associated with biologics are reported. Many were associated with tumor necrosis factor α (TNFα) inhibitors, moreover, cases even associated with other family biologics were reported in Japan.To analyze the background factors of patients who developed ILD, […]
- Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.We wish to bring your attention to the PsoPROTECT (Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of Covid-19 infecTion) and SECURE-AD (Surveillance Epidemiology of Coronavirus Under Research Exclusion-Atopic Dermatitis) registries; two urgent global initiatives that address an unmet need for delineating the determinants of COVID-19 outcomes in the common cutaneous immune-mediated inflammatory diseases (IMIDs) […]
- The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience.The “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic [1]. As of April 1, 2020, more than one million COVID-19 positive cases have been identified and more than 54,000 deaths have occurred worldwide [2]. […]
- Partner bereavement can increase the incidence of atopic dermatitis but has no effect on psoriasis.Click here to read the full article @ The British journal of dermatology
- Evaluation of the fragility of pivotal trials used to support FDA approval for plaque psoriasis.Over the last five years, there has been a rapid growth in the number of clinical trials used to support an FDA approval for systemic therapies with labeled indications for plaque psoriasis.We aim to evaluate the fragility of clinical trial data used to support FDA-approval of therapies for psoriasis.We reviewed primary endpoints of the efficacy […]